WO2010127420A1 - Sequências geneticamente modificadas de antígenos de plasmodium vivax - Google Patents
Sequências geneticamente modificadas de antígenos de plasmodium vivax Download PDFInfo
- Publication number
- WO2010127420A1 WO2010127420A1 PCT/BR2009/000130 BR2009000130W WO2010127420A1 WO 2010127420 A1 WO2010127420 A1 WO 2010127420A1 BR 2009000130 W BR2009000130 W BR 2009000130W WO 2010127420 A1 WO2010127420 A1 WO 2010127420A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- recombinant
- malaria
- ama
- protein
- Prior art date
Links
- 108091007433 antigens Proteins 0.000 title claims abstract description 33
- 102000036639 antigens Human genes 0.000 title claims abstract description 33
- 239000000427 antigen Substances 0.000 title claims abstract description 32
- 241000223810 Plasmodium vivax Species 0.000 title claims abstract description 29
- 229960005486 vaccine Drugs 0.000 claims abstract description 34
- 108010057081 Merozoite Surface Protein 1 Proteins 0.000 claims abstract description 31
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 31
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 31
- 241000700605 Viruses Species 0.000 claims abstract description 31
- 230000003053 immunization Effects 0.000 claims abstract description 27
- 238000002649 immunization Methods 0.000 claims abstract description 27
- 201000004792 malaria Diseases 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 238000002255 vaccination Methods 0.000 claims abstract description 13
- 101150078331 ama-1 gene Proteins 0.000 claims abstract description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 38
- 230000028993 immune response Effects 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 241000700618 Vaccinia virus Species 0.000 claims description 9
- 241000598171 Human adenovirus sp. Species 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 67
- 102000004169 proteins and genes Human genes 0.000 abstract description 54
- 239000013598 vector Substances 0.000 abstract description 23
- 238000010276 construction Methods 0.000 abstract description 13
- 230000002068 genetic effect Effects 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract 1
- 101710203310 Apical membrane antigen 1 Proteins 0.000 description 51
- 235000018102 proteins Nutrition 0.000 description 49
- 238000010367 cloning Methods 0.000 description 38
- 239000013612 plasmid Substances 0.000 description 31
- 239000012634 fragment Substances 0.000 description 27
- 108010076504 Protein Sorting Signals Proteins 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- 230000029087 digestion Effects 0.000 description 18
- 230000009545 invasion Effects 0.000 description 12
- 241000701022 Cytomegalovirus Species 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 11
- 230000003321 amplification Effects 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 241001135569 Human adenovirus 5 Species 0.000 description 10
- 241000223960 Plasmodium falciparum Species 0.000 description 10
- 210000003936 merozoite Anatomy 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 241000712461 unidentified influenza virus Species 0.000 description 9
- 241000224016 Plasmodium Species 0.000 description 8
- 108020005202 Viral DNA Proteins 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 101710132601 Capsid protein Proteins 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000235058 Komagataella pastoris Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 108020000999 Viral RNA Proteins 0.000 description 7
- 239000013256 coordination polymer Substances 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 229940124735 malaria vaccine Drugs 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 230000024932 T cell mediated immunity Effects 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 244000045947 parasite Species 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 210000003046 sporozoite Anatomy 0.000 description 5
- 229940125575 vaccine candidate Drugs 0.000 description 5
- 108010056962 Adenovirus E4 Proteins Proteins 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000007969 cellular immunity Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000235648 Pichia Species 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 102100036826 Aldehyde oxidase Human genes 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 101710145634 Antigen 1 Proteins 0.000 description 2
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 2
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 101900058136 Plasmodium falciparum Apical membrane antigen 1 Proteins 0.000 description 2
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 102000025171 antigen binding proteins Human genes 0.000 description 2
- 108091000831 antigen binding proteins Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000012215 gene cloning Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101710170920 62 kDa protein Proteins 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 102100034612 Annexin A4 Human genes 0.000 description 1
- 108090000669 Annexin A4 Proteins 0.000 description 1
- 241000282708 Aotus <primate> Species 0.000 description 1
- 101000705294 Arabidopsis thaliana Oxygen-evolving enhancer protein 1-2, chloroplastic Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000579120 Coliiformes Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 241000274183 Micromeria Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 1
- 201000009976 Plasmodium vivax malaria Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 101710146343 Scaffold protein D13 Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102000008230 Toll-like receptor 3 Human genes 0.000 description 1
- 108010060885 Toll-like receptor 3 Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 208000005469 Vivax Malaria Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 229940021704 adenovirus vaccine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 244000096108 cunha Species 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 230000026502 entry into host cell Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the construction of modified genetic sequences comprising sequences for Plasmodium vivax antigens (DBP-PA, DBP-AM, AMA-1, CS and MSP-1), their recombinant proteins encoded by said sequences. genetically modified sequences and viruses expressing recombinant antigens. Further, the present invention relates to a prime-boost vaccination method using adenoviral or poxviral vectors, purified mammalian immunization proteins and vaccine compositions useful for use as a malaria vaccine.
- Malaria is considered by WHO to be one of the three most important infectious diseases today and there is no licensed vaccine against the disease so far.
- the most prevalent causative parasites in the world are P. vivax and P. falciparum, the first being the most frequent in Brazil where malaria is a serious public health problem aggravated in recent years by the increase in the number of cases. Due to the large genetic difference between the two parasites, the need for the development of differentiated vaccines is accepted. Much research has favorably pointed to the feasibility of malaria vaccines.
- Recombinant viruses have been shown to be efficient for vaccine development.
- Clinical trials with recombinant virus-based vaccine candidates for malaria, tuberculosis and AIDS show unprecedented levels of cellular immune response against recombinant virus-expressed products, as compared to vaccine formulations based on purified recombinant proteins or plasmid DNA vaccines (ROCHA).
- Recombinant viruses as tools to induce protective cellular immunity against infectious diseases (Int. Microbiol. 2004. 7, 89-94).
- Recombinant viral vectors are currently proven to be effective vaccine vehicles. Of these, the most used are the Poxvirus, Influenza virus and Adenovirus, and some studies with the latter are in advanced stage of clinical trials for diseases such as malaria and AIDS.
- recombinant viruses an advantage in the use of recombinant viruses is that the viral particle itself has an adjunct effect by itself, which avoids the use of other adjuvant compounds or cytokines. Therefore, recombinant adenoviruses, influenza viruses, vaccinia viruses (MVA) stand out for their immunomodulatory properties (GUILLOT L, LE GOFFIC R., BLOCK S., WRITTEN N., AKIRA S., CHIGNARD M. SITAHAR M. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus (J. Biol. Chem. 2003. 280, 5571-5580).
- the Adenovirus Capsid Protein Hexon Contains a Highly conserveed Human CD4 + T-Cell Epitope. Hum. Gene Ther., 13 : 1167-1178) and CD8 + T cells (Fitzgerald, Julie C; Gao, Guang-Ping; Reyes-Sandoval, Arturo; Pavlakis, George N.; Xiang, Zhi Q .; Wlazlo, Anthony P.; Giles-Davis, Wynetta; Wilson, James M.; Ertl, Hildegund GC 2003. Simian Replication-Defective Adenoviral Recombinant Vaccine to HIV-1 Gag. J. Immunol., 170: 1416-1422).
- recombinant poxvirus construction techniques including the MVA virus (Modified Vaccinia Ankara Virus), involve the homologous recombination of DNA into infected cells.
- MVA virus Modified Vaccinia Ankara Virus
- recombinant virus production employs transfer plasmid vectors containing an expression cassette where the exogenous gene is controlled by a strong promoter, usually early and late, of poxviruses. This cassette is flanked by DNA sequences homologous to the sequences present in the virus genome, and will serve to direct recombination to the desired locus.
- the recombination rate is relatively high, around 0.1%, and recombinant viruses can be screened, plaque purified and amplified.
- adenoviruses ideal candidates for vaccine development are: low pathogenicity to humans, inability to integrate into the host genome, ease of purification resulting in high viral titers and the ability to infect multiple cells, including dendritic cells (Rocha, Carolina Damas; Caetano, Bráulia Costa; Machado, Alexandre Vieira; Brufia-Romero, Oscar. 2004. Recombinant viruses as tools to induce protective cellular immunity against infectious diseases. Int. Microbiol., 7: 83- 94).
- vaccinia virus As a vaccine vector, (i) genome capable of accommodating large exogenous DNA fragments and expressing recombinant proteins, (ii) replication occurs in the cellular cytoplasm, which prevents the genome integrate with host genetic material, (iii) ease of purification, (iv) ability to generate transgene-specific long-lasting lymphocytes inserted into their genome after a single immunization (Rocha, Carolina Damas; Caetano, Bráulia Costa; Machado, Alexandre Vieira; Bruna-Romero, Oscar 2004. Recombinant viruses as tools to induce protective cellular immunity against infectious diseases (Int. Microbiol., 7: 83-94).
- the homologous protocols are more advantageous from the point of view of vaccine construction, since only one type of vaccine needs to be developed (a single vector to be applied in immunizations).
- the heterologous protocol in turn, two vaccines need to be developed, each containing one of the vectors to be used in immunizations.
- the six or eight week interval used in the present invention between the two immunizations has been shown to be effective in restimulating the primary immune response induced after the initial vaccination, demonstrating that, after that time, pre-existing immunity decreased to levels that allow the action of a second dose of vaccine.
- WO07003384A1 describes a novel use of a malarial antigen useful for immunization against malaria.
- This invention relates to the use of sporozoite antigens, particularly CS protein or derived immunogenic fragments, combined with suitable adjuvants.
- US20050100558A1 describes vaccination methods for generating an effective antigen-specific immune response.
- the invention describes the use of heterologous vaccination vectors to elicit a potentiated immune response.
- Methods for treating and preventing diseases using the vaccination scheme of the present invention are also disclosed.
- Patent document WO06040334A1 describes new vaccine regimens based on the prime-boost scheme. Neutralized recombinant adenoviral vectors expressing P. falciparum antigens were used. Vaccines based on recombinant DNA technology, along with appropriate adjuvants, are also described.
- US20040131594A1 describes methods and reagents for vaccination that are capable of generating a CD8 T cell immune response against malarial, viral or tumor antigens.
- New vaccine regimens are described and employ an initial composition (prime) and another enhancer ⁇ boost).
- the enhancer composition comprises the use of non-replicative or replicative-deficient poxviral vectors expressing at least one CD8 T cell epitope which is also present in the initial composition.
- US20060188527A1 is a new method for protection against malarial infection through vaccination.
- the invention comprises the induction of an initial anti-malaria response by the use of DNA-based vaccine and, sequentially, a booster immunization using a protein vaccine is used.
- Saccharomyces cerevisiae was the first yeast used for the purpose of producing exogenous proteins due to the knowledge about this organism, besides the acceptance for use of this yeast in experiments for human benefit (CREEG et al., 1993).
- the S. cerevisiae expression system did not meet all expectations due to secretion and productivity inefficiency, hyperglycosylation, instability of the producing strains, difficulties in maintaining high growth rates and high population densities of recombinant cells ( SWINKELS et al., 1993).
- SWINKELS et al., 1993 Several studies have been and are being done to use alternative yeasts for the production of recombinant proteins.
- Pichia pastoris whose expression system has been designed, is shown to be an efficient host for the synthesis and secretion of heterologous proteins for clinical, academic or industrial applications (COS et al, 2005).
- Pichia pastoris is a methylotrophic yeast capable of growing to high cell densities (in the order of grams per liter) and the concentration of recombinant proteins produced is often proportional to the biomass achieved (HINGGS, 1998).
- HINGGS Several examples show that Pichia can achieve much higher yields than S. cerevisiae, E. coli or baculovirus (CREGG, VEDVICK and RASCHKE, 1993; ROMANOS et al., 1992).
- Pichia system The success of the Pichia system is largely related to the AOX1 promoter of the gene encoding the enzyme alcohol oxidase which is repressed in glycerol-containing culture medium but induced when cells are transferred to methanol-containing medium as the sole carbon source (HINGGS). , 1998; CREEG 1999; BOETTNER et al., 2002).
- P. pastoris Since one copy of the gene is integrated per transformed cell, increasing population density increases protein yield (CREEG et al., 1993).
- P. pastoris has other advantages such as: high regulation by the AOX1 promoter; low glycosylation (often similar to human protein glycosylation); the simplicity of protein expression induction by methanol; the low level of native protein secretion; besides growing in simple or defined medium, using methanol as the sole carbon source (CREEG et al., 1993; DIGAN et al., 1989; CHEN et al., 1996; NOHR et al., 2003; WITTAKER et al., 2004; COS, et al., 2005).
- the growth medium for P. pastoris in recombinant protein production is defined, inexpensive and ideal for large scale production.
- the medium is free of complex ingredients that could generate toxins and is therefore easily accepted for use in drug production (CHEN et al., 1996; GELLISSEN et al., 2005).
- IGF-1 insulin-like growth factor 1
- HSA insulin-like growth factor 1
- the expression of P. vivax DBPII by this system may be one of the most viable ways of obtaining a protein. biologically active protein allowing its use as an antigen in the immunization process and with potential to be used for human use.
- malaria immunization may be based on the Duffy antigen-binding protein in erythrocytes that is called DARC and which has specificity for its ligand to the plasmid Duffy-Binding Protein.
- DARC Duffy antigen-binding protein
- This erythrocytic invasion involves a complex cascade of events and requires specific interaction between erythrocyte receptors and parasite proteins.
- P. vivax infection has been reported to be entirely dependent on this Duffy interaction with the human erythrocyte. Much of the population in Africa is reported to be resistant to P. vivax infection and this is due to the fact that the observed population does not have the DARC receptor, which prevents covalent interaction of BPD. This makes DBP an excellent vaccine candidate, since antibodies directed against this region could block the interaction of DBP with the erythrocyte in populations where P vivax is a major cause of malaria.
- the BPD region responsible for erythrocyte binding comprises protein II region. This region is rich in cysteine, which guarantees its structural conformation and also rich in polymorphisms, which allows evasion to the host immune system.
- P. vivax BPD region II has been described as PvDBPII.
- AMA-1 Apical membrane antigen 1
- HODDER AN
- CREWTHER CREWTHER
- PE CAM-A
- ANDERS RF. Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immun. V 69, No. 5: pp. 3286-3294, 2001).
- AMA-1 is stored in the micronema after synthesis and subsequently translocated to the parasite surface via roptria or during host cell invasion.
- AMA-1 is synthesized as a 66KDa transmembrane protein except for P. falciparum. It is a typical integral protein with an N-terminal ectodomain, a transmembrane region, and a small C-terminal cytoplasmic domain (KOCKEN, CHM; WITHERS-MARTINEZ, C; DUBBELD, MA; WEL, A .; HACKETT, F .; BLACKMAN, MJ; THOMAS, AW High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit trocyte invasion Infect. Immun. V.70, No. 8; p.4471-4476 , 2002).
- the AMA-1 gene shows 16 ectodomain conserved Cys residues (PIZARRO, JC; NORMAND, BV; et al. Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science, v.308, p .408-411, 2005) and is divided into three domains defined by 8 disulfide bridges (HODDER, AN; CREWTHER, PE; MATTHEW, MLSM; REID, GE; MORITZ, RL; SIMPSON, RJ; ANDERS, RF of Plasmodium apical membrane antigen-1 (J. Biol. Chem. v 271, no. 46; p. 29446-29452, 1996).
- HODDER 8 disulfide bridges
- P. vivax AMA-1 ectodomain (PvAMA-1), corresponding to residues Pro 43 to Leu 487 confirms the division into three domains, and that domains I and II are structurally similar to other proteins belonging to the superfamily.
- PAN whose proteins have a function related to adhesion and binding to receptors or other proteins.
- domain II has a disorder or mobility region corresponding to residues 295 to 334, called the domain II loop (PIZARRO, JC; NORMAND, BV; et al. Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science, v. 308, p.408-411, 2005).
- AMA-1 is produced as an 83Kda polypeptide that undergoes processing after synthesis in which a small N-terminal fragment is proteolytically cleaved, yielding mature 62-Kda protein (CREWTHER, PE; CULVENOR, JG ; SILVA, A .; COOPER, JA; ANDERS, RF Plasmodium falciparum: two antigens of similar size are located in different compartments of the rhoptry (Exp. Parasitol. V 70, no. 2, p. 193-206, 1990).
- the ability of this molecule to induce protective immune response depends on the stability of its disulfide bond conformation (HODDER, AN; CREWTHER, PE; MATTHEW, MLSM; REID, GE; MORITZ, RL; SIMPSON, RJ; ANDERS, RF structure of Plasmodium apical membrane antigen- 1. J. Biol. Chem. v 271, no. 46; p.29446-29452, 1996), as inhibitory antibodies preferentially react with disulfide-stabilized conformation epitopes (HODDER, AN; CREWTHER, PE; ANDERS, RF. Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immun (69, No. 5; pp. 3286-3294, 2001).
- AMA-1 sequence is relatively conserved among Plasmodium species, with the level of amino acid sequence identity exceeding 50% in comparisons between all known sequences (CHENG.Q .; SAUL, A. Sequence analysis of the apical membrane. antigen 1 (AMA-1) of Plasmodium vivax (Mol. Biochem. Parasitol. v 65; p.183-187, 2004).
- AMA-1 has no repetitive sequences and the polymorphism found in other antigens such as MSP-1 and MSP-2 (ANDERS, RF, SMYTHE, JA Polymorphic antigens in Plasmodium falciparum. Blood. V.74; p.1865-1875 , 1989).
- AMA-1 The biological function of AMA-1 is not yet known, but there is evidence that this protein is involved in the process of merozoite invasion of the erythrocyte (KOCKEN, CHM; WITH ERS-MARTI N EZ, C; DUBBELD, MA; WEL, A. ; HACKETT, F;; BLACKMAN, MJ; THOMAS, AW High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erytrocyte invasion.
- Phage-displayed peptides bind to te malarial protein apical membrane antigen-1 and inhibit the merozoite invasion of host erythocytes (J. Biol. Chem. v 277, No. 52; p.50303-50310, 2002).
- AMA-1 targeted monoclonal antibodies were able to inhibit the invasion of merozoites, showing that AMA-1 acts in the invasion process (CREWTHER et al., 1990).
- Mitchell et al. (2004) suggest that this protein is directly responsible for the reorientation of the merozoites during the invasion process or that AMA-1 may initiate the contact junction and relies on Duffy binding proteins for the process to occur effectively (MITCHELL, GH; THOMAS, AW; MARGOS, G .; DLUZEWSKI, AR; BANNISTER, LH Apical membrane antigen 1, the major malaria vaccine candidate, mediates the dose attachment of invasive merozoites to host red blood cells. 1; p.154-158, 2004).
- AMA-1 is also involved in hepatocyte invasion, protein is no longer expressed after sporozoite invasion of hepatocyte and is re-expressed only in the Merozoites. Inhibition of sporozoite invasion by anti-AMA-1 antibodies indicates that AMA-1 can be considered as a potential candidate for multi-stage malaria vaccine, targeting both erythrocyte and pre-erythrocyte stages (SILVIER, 0.; FRANETICH JAR; CHARRIN, S.; MUELLER, MS et al. A role for apical antigen 1 during invasion of hepatocytes by P. falciparum sporozoites J. Biol. Chem. V. 279 (10), p.9490-6, 2004 ).
- Antibodies against AMA-1 are known to inhibit parasite multiplication in vitro and in vivo when interacting with the surface of merozoites.
- AMA-1 vaccine studies in animal models have shown that immunization with this purified or recombinant protein induced protective immune response when animals were challenged with Plasmodium species.
- the 19 Kda C-terminal protein fragment is a major candidate for the vaccine.
- Several studies demonstrate that it is capable of triggering protective immune response (KUMAR, S .; COLLINS, W.; EGAN, A.; YADAVA, A.; GARRAUD, O.; BLACKMAN, MJ; PATINO, JAG; DIGGS, C; KASLOW , DC Immunogenicity and efficacy in Aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1.
- P. vivax MSP-1 (PvMSP1 19 ), similarly to MSP-1 19 from other Plasmodium species studied, consists of a pair of EGF-like (epidermal growth factor) domains presenting multiple interdomain contacts, and are closely aligned. anti-parallel to each other. This results in a U-shaped conformation that leaves the C and N-terminal ends intimately close (BABON, JJ; MORGAN, WD; KELLY.G .; ECCLESTON, JFHOLDER, AA. Structural studies on P. vivax merozoite surface protein-1. Mol. Biochem, Parasitol, V.153, p.31-40, 2007).
- a multi-stage vaccine containing antigen specific for pre-erythrocytic and erythrocytic parasitic forms appears to be the most efficient alternative to protect against malaria.
- Administration in priming and booster protocols that induce high simultaneous levels of long-term cellular and humoral immunity of these recombinant antigens, using recombinant viruses (adenovirus and / or poxvirus) and recombinant proteins as immunization vehicles, are choices most likely to be. protect against malaria.
- the present invention relates to the construction of modified genetic sequences comprising P. vivax antigen sequences (DBP-PA, DBP-AM, DBP-MT, AMA-1, CS and MSP-1), their recombinant proteins encoded by said genetically engineered sequences and viruses expressing recombinant antigens. Further, the present invention relates to a prime-boost vaccination method using adenoviral or poxviral vectors, purified mammalian immunization proteins and vaccine compositions useful for use as a malaria vaccine.
- Duffy - Duffy Binding Protein or DBP - antigen binding protein against P. vivax malaria has been modified.
- construction of an adenovirus secreting the recombinant protein in the extracellular medium is described due to incorporation of the HASS signal peptide into the viral vector.
- the construction is characterized by the combination of polymorphisms found in the Brazilian population in order to increase vaccine coverage.
- sequences from patients from the Brazilian endemic area were used.
- the DBP-PA, DBP-MT and DBP-AM sequences represent the three most frequent DBP protein polymorphisms present in Brazil, and the administration of these sequences are of fundamental importance in inducing a protective vaccine response.
- the digestion product was purified and cloned into pcDNA3.1 HASS containing the influenza virus signal peptide that allows protein secretion by adenovirus.
- the cloning was done between the EcoRI and Xba ⁇ site of this plasmid. Positive clones were digested to obtain the HASS-DBPII portion that was cloned into pADCMV-linkl in phase to the cytomegalovirus expression promoter. Positive clones were sequenced to confirm correct insertion into the plasmid.
- PADCMVLinkl -HASS-DBPII was used to homologously recombine pJM17 with another plasmid. This recombination phenomenon occurs during transfection and allows the generation of adenoviruses 5.
- Another recombinant protein was obtained from the amino acid sequence of the P. vivax CS Belem strain CS protein (Gene Bank-accession AAA29526). Epitopes of the CS protein described in the literature were chosen and inserted into strategic points of the HBcAg protein as detailed above (Fig. 6). The structural conformation of the recombinant protein designed to predict its similarity with the structure of HBcAg monomers described earlier by Böttcher et al. (1997). The result of this prediction was provided by the Swiss-Pdb Viewer server from the amino acid sequence of the recombinant protein and revealed that despite the exogenous amino acid insertions derived from the CS- protein the conformational structure remains the same.
- the nucleotide sequence was predicted by optimizing the choice of codons for the human model. Restriction enzyme sites for the cloning process for the construction of the recombinant virus were also inserted. Based on the optimized gene sequence a synthetic gene was produced by Entelechon (Fig. 7). At the Bgl ⁇ / Nco ⁇ site of the synthetic gene the IRES sequence was cloned. Both types of constructs (HBc-CS and HBc-CS-IRES) were cloned into the Bgl ⁇ IKpn ⁇ sites of plasmid pAdCMV-link-1 (Fig. 8).
- pJM17 contains the insert-modified human adenovirus genome (pBRX) in the E1 region.
- pAdCMV-link-1 contains, flanking the cloning site, a Cytomegalovirus (CMV) promoter, a polyadenylation site (poly A), and homology regions with human adenovirus type 5.
- CMV Cytomegalovirus
- poly A polyadenylation site
- the homology regions in pAd-HBc-CS and pAd-HBc-CS-IRES are paired and recombined with pJM17 and the transgene expression cassette is transferred to the adenovirus 5 genome, deleting the pBR insert.
- a non-replicating human adenovirus type 5 capable of expressing P. vivax MSP-1 19 (PvMSP-1 19 ) vaccine antigen in HEK293A was also developed.
- the use of a viral vector is justified by the fact that it mainly induces a cellular immune response and acts as an adjuvant enhancing the immune response.
- AdMSP-1 19 a cloning strategy of the gene coding for P. vivax MSP-1 19 in pAdCMV-Link-1 was developed.
- the recombinant protein expressed by adenovirus corresponds to the P.
- vivax MSP-1 amino acid sequence 1616-1704 BELÉM strain, and has a histidine tail in the N-terminal region and in the C-terminal region a fusion with the universal CD4 epitope FATHER (Pan Allelic DR Epitope) (CUNHA et al., 2002).
- this recombinant protein also has an influenza virus signal peptide (HASS) which allows its secretion into the extracellular medium.
- HASS influenza virus signal peptide
- Another vaccine antigen expressed by the recombinant adenovirus corresponds to P. Vax's AMA-1 ectodomain, referring to residues Pro 43 to Leu 487 of P. vivax isolate BEL-12, fused to the influenza virus signal peptide (HASS) which allows directing AMA-1 to the extracellular medium inducing humoral immune response leading to the generation of specific antibodies.
- the recombinant virus was generated by homologous recombination, and the P. vivax AMA-1 ectodomain coding region contained in the pAdCMV-Link-1 transfer vector was inserted into the adenovirus genome.
- the recombinant protein expressed by adenovirus corresponds to the P.
- v / Vax AMA-1 amino acid sequence 43 - 487 of the BEL-12 isolate from a patient from Belém-PA which was obtained from plasmid pHIS- AMA-1 (RODRIGUES, MHC; RODRIGUES, KM; OLIVEIRA, TR; CODE, AN; RODRIGUES, MM; KOCKEN, CHM; THOMAS, AW; SOARES, IS Antibody Response of naturally infected individuals to recombinant Plasmodium vivax Int. J. Parasitol, v35, p185-192, 2005).
- this recombinant protein also has an influenza virus signal peptide (HASS) which allows its secretion into the extracellular medium.
- HASS influenza virus signal peptide
- Non-replicative human adenovirus type 5 is capable of expressing, in HEK293A cells, the P. vivax AMA-1 vaccine antigen (PvAMA-1).
- PvAMA-1 vaccine antigen
- the use of a viral vector is justified by the fact that it mainly induces a cellular immune response and acts as an adjuvant enhancing the immune response.
- the vaccine antigen expressed by the recombinant adenovirus corresponds to P. vivax AMA-1 ectodomain, referring to residues Pro 43 to Leu 487 of P. vivax isolate BEL-12, fused to the influenza virus signal peptide (HASS) which allows directing AMA-1 to the extracellular medium inducing humoral immune response leading to the generation of specific antibodies.
- HASS influenza virus signal peptide
- the prime-boost protocol of the present invention is based on the sequential administration of the recombinant adenovirus (human adenovirus type 5 or HuAdS) vaccine vector and recombinant vaccinia virus (WR, Copenhagen or MVA strains) capable of expressing a common heterologous protein or these proteins administered in their purified recombinant form.
- the homologous dose booster protocol consists of the administration of the same viral vector or purified recombinant proteins in both immunizations (Ad / Ad or Prot / Prot) whereas the heterologous protocol is characterized by the use of a viral vector or recombinant protein at the booster dose.
- Booster dose may further be performed using purified antigenic pathogen proteins following administration of adenovirus or vaccinia at the initial dose or vice versa.
- the interval between immunizations used was 6 or 8 weeks, never less than 35 days in any case.
- Example 1 Construction of DBPII Recombinant Adenoviruses From region II primers were designed containing enzyme restriction sites for the enzymes EcoRI and Xba ⁇ which were used for insertion of the sequence of interest into the pPIC9Z vector for P. pastoris yeast transformation and also for insertion into pTopoTA and subsequent cloning. in pcDNA3.1 HASS to obtain the influenza virus HASS signal peptide and then cloning HASS-DBPII into pAdCMV-linLysl.
- This latter plasmid was used to homologously recombine with pJM17 to generate adenoviruses expressing DBPII.
- the DBPII sequence obtained by PCR from the sera of these patients was individually cloned into the plasmids and the same procedure was adopted in the DBPII cloning steps.
- HBcAg hepatitis B virus core protein
- CS protein epitopes located at specific points in this molecule is made by the inclusion of the repeated three times P. vivax epitope B (GDRADGQPA) in the immunodominant loop of HBcAg, that is, between amino acids 78 and 79.
- HBcAg In the N-terminal portion of HBcAg is the signal peptide of the influenza virus hemagglutinin protein (HASS signal peptide).
- HASS signal peptide the signal peptide of the influenza virus hemagglutinin protein
- HBcAg molecule is truncated at amino acid 149, where an internal ribosome entry site (i.e. an IRES sequence) is located.
- portions of the P. vivax CS protein are present which include B, TCD4 and TCD8 epitopes. Such portions are arranged in six blocks separated by epitope spacers that facilitate their processing by the cell as follows: block 1: amino acids 1 through 23 of the Belém sample CS protein comprising a human TCD8 epitope between the amino acid sequence AAY (spacer) on each side; block 2: amino acids 264 to 272, comprising a human TCD8 epitope, flanked by the AAY spacer; block 3: amino acids 292 to 378, comprising epitopes B, TCD4 and TCD8, flanked by the AAY spacer; block 4: cytomegalovirus murine TCD8 epitope flanked by the AAY spacer; block 5: amino acids 301 to 309, comprising a human TCD8 epitope, flanked by the AAY spacer; block 6: amino acids 51 to 90, comprising epitopes B and TCD4, flanked at
- Transfer plasmids basically consist of generic plasmids (such as pUC19) to which gene portions called Insert and Expression Cassettes are added ( Figure 6).
- the insertion cassette consists of: Nucleotide sequence homologous to the 5 ' portion of the Deletion Region II and / or Deletion Region III of the MVA genome (1 ); Early / late modified promoter of Vaccinia virus (2); marker protein coding gene - Fluorescent Green Protein (GFP) or Fluorescent Red Protein (RFP) (3); cDNA / Gene cloning site of interest (4), Early / late modified Vaccinia virus promoter (5); nucleotide homologous to the 3 ' portion of the Deletion Region II and / or Deletion Region III of the MVA genome (6).
- MSP-1 Merozoite surface protein 1
- GPI glycosylphosphatidylinositol
- a second cleavage separates the 19Kda C-terminal fragment from the protein complex, and only the membrane-bound portion via the GPI anchor is transferred to the newly infected erythrocytes (KAUTH, CW; EPP, C; BUJARD, H. LUTZ, R.
- the merozoite surface protein 1 complex of human malaria parasite P. falciparum TJ Biol. Chem. V278, No. 25, p.22257-22264, 2003).
- the gene sequences encoding the P. vivax MSP-119 proteins were PCR amplified from plasmid pET-MSP1-PADRE with the 5 'GCA GAT ATC sense primers CAT CAC CAT CAC CAT CAC and antisense 5 AAG CTT TTA AGC GGC AGC CTT CAG GGT.
- the highlighted codons are the sites for the restriction enzymes EcoRV and Hind ⁇ , respectively, and the underlined codon corresponds to the stop codon.
- PCR reactions were performed with the high fidelity enzyme Pfx (Invitrogen) according to the manufacturer's instructions and under the following amplification conditions: one cycle of 5min at 94 ° C, 38 cycles of 40sec at 94 ° C, 45sec at 45 ° C and 1: 30min 68 ° C and a final extension cycle of 4min at 68 ° C.
- Pfx Invitrogen
- MSP primers specific for 9-11 was amplified a fragment of 399 bp from the pET-19 -PADRE MSP-1, which was cloned into pCR-blunt II TOPO. In this cloning, TOPO-MSP-1 19 was created and Figure 13 shows the selection of positive clone.
- both the vector as the top- MSP-1 19 clones were digested with Eco RV and Hind ⁇ . After digestions the desired fragments were purified by the Qiaquick gel extraction kit (QIAGEN). Then were cloned into the vector. In this cloning pAdCMV-MSP-1 19 was created. Positive clones show a 388bp fragment after digestion with EcoRV and Hind? As shown in Figure 14.
- the pAdCMV-MSP-1 19 was digested with Bgl II to linearize the plasmid and pAd32.1 was digested with BamHI yielding a fragment of 717pb. After digestion the fragments were then purified and ligated as mentioned above. In this cloning the partial pAdCMV-HASS-MSP-1 19 was created. Screening of positive clones was done with Not ⁇ , and positive clones have 1200 bp fragments, as shown in Figure 15.
- Positive clones pAdCMV-HASS-MSP-1 i 9 part were digested with EcoRV to remove additional bases 625 bases.
- the linearized plasmid was subsequently cut from the gel and purified with T4 DNA ligase was circularized again, yielding HASS pAdCMV-9-MSP-11. Selection of positive clones was done by Not ⁇ digestion, as shown in Figure 15.
- Example 6 - PCR And RT-PCR of HEK 293A cells infected with recombinant adenovirus to confirm presence of transgene.
- 400bp amplifications with the primers specific for MSP- 19 were obtained from DNA and RNA extracted from HEK293A cells infected with AdMSP-1 recombinant virus 19 .
- the reverse transcription reaction was performed and the originated cDNA was treated with DNAse.
- adenovirus E4 gene specific primers that amplify a 500bp fragment.
- Example 7 Detection of recombinant proteins by antibodies.
- HEK293A cell extract infected with recombinant adenovirus AdMSP-1 19 showed intense reactivity with serum from BALB / c mice immunized with MSP-1 19 by western blot assay. This result confirms the expression of MSP- 19 by AdMSP- 19 .
- Animals were immunized subcutaneously with 200 ⁇ emulsion Montanide ISA 720 (30:70 protein / oil) with 20 ⁇ 9 of purified AMA-1 protein. Two immunizations were made with a 3 week interval between them, in each immunization, 50 ⁇ were applied at 4 different points on the back of the animal, totaling 200 ⁇ . Sera were collected 14 days after the last immunization.
- the gene sequences encoding P. vivax AMA-1 proteins were PCR amplified from plasmid pHIS-AMA-1 with the 5 'sense primers GCA GAT ATC GGC AGC AGC CAT CAT CAT and antisense 5 'GGT ACC TTA TAG TAG CAT CTG CTT GTT.
- the highlighted codons are the sites for the restriction enzymes EcoRV and Kpn ⁇ , respectively, and the underlined codon corresponds to the stop codon.
- PCR reactions were performed with the high fidelity enzyme Pfx (Invitrogen) according to the manufacturer's instructions and under the following amplification conditions: one cycle of 5min at 94 ° C, 38 cycles of 40sec at 94 ° C, 45sec at 45 ° C and 1h30min 68 ° C and a final extension cycle of 4min at 68 ° C.
- Pfx High fidelity enzyme
- PAd32.1 containing the HASS signal peptide was used.
- PAdCMV-AMA-1 was digested with Bgl ⁇ which linearizes the plasmid, and pAd32.1 with BamH ⁇ , yielding a 717bp fragment, 92 bases corresponding to HASS and the remaining 625 bases served to facilitate cloning ( Figure 22 ).
- Sg11 and SamHI have compatible ends, that is, Bgl II generated ends can be directly linked to Bam ⁇ ends, but their restriction sites are not regenerated, as depicted in Figure 23.
- Example 10 - PCR and RT-PCR from HEK 293 cells infected with recombinant adenoviruses to confirm presence of transgene
- AMA-1 specific primers were obtained from DNA and RNA extracted from HEK293A cells infected with the AdAMA-1 recombinant virus. For total RNA the reverse transcription reaction was performed and the originated cDNA was treated with DNAse. In addition to the AMA-1 specific primers we also used adenovirus E4 gene specific primers that amplify a 500bp fragment. These amplifications from viral DNA and viral RNA indicate that the recombinant adenovirus is expressing AMA-1. Figure 26 demonstrates the amplifications.
- Detection of recombinant proteins by antibodies was done by western blot. Serum antibodies from BALB / c mice immunized with the recombinant proteins were used as primary antibodies. As a secondary peroxidase conjugated anti-mouse antibody (Zymed).
- FIGURE 01 PCR amplified DBPII cloning at the Eco RI and Xba I sites of plasmid pTopoTA.
- FIGURE 02 Cloning of DBPII taken from pTopoTA with the EcoRI and Xbal enzymes at the pcDNA3.1HASS EcoRI and Xbal enzyme sites for addition of the HASS signal peptide. The same procedure was adopted for the three patients; AM, MT and PA.
- FIGURE 03 (A) Schematic representation of the cloning site in pAdCMV-linLysl-HASS-DBP AM, MT and PA. (B) The CMV promoter and SV40 tail. DBP AM was cloned into the EcoRV site of this plasmid. The arrows indicate the position of the primers.
- FIGURE 04 Scheme depicting homologous recombination occurred between pAdCMV-linLys-1 and pJM17 during transfection of HELYS293 cells for generation of DBPII-expressing adenoviruses.
- FIGURE 05 DBPII cloning scheme in vector pPIC9Z used for transformation of P. pastoris yeast by electroporation. The cloned sequence in pAdCMV-linLys-1 will be removed by the EcoRI and Xoal enzymes thus displacing the HASS signal peptide sequence. DBPII will be cloned into pPIC9Z at the respective EcoRI and Xbal sites and will have as signal peptide the S. cerevisiae meeting-alpha factor present in the pPIC9z expression system. At the end of the DBPII sequence there will be six histidine residues.
- FIGURE 06 Design of the recombinant vaccine protein highlighting its portions: "HASS” signal peptide amino acid sequence,
- HBcAg amino acid sequence (aa 1 to 78 and thereafter aa 79 to 149) and CS protein derived epitopes. 1: repetitive portion, containing epitope B and T CD4
- FIGURE 07 Plasmid pAdCMV-link-1 schema showing regions of homology to the Ad5 genome, cytomegalovirus promoter, polyadenylation site and cloning site.
- FIGURE 08 (3): (A) Transfer plasmid for construction of recombinant MVA viruses.
- GFP Green Protein
- RFP Fluorescent Red Protein
- FIGURE 09 A. Transfer vector pAdCMV-Link-1: Cytomegalovirus (CMV) promoter, Cloning Site, polyadenylation site (poly A), HAdV5 homology regions. mu: map unit.
- FIGURE 10 Plasmid pJM17: contains the insert-modified human adenovirus genome (pBRX) in the E1 region, located between the Xba ⁇ sites.
- FIGURE 11 Schematic representation of homologous recombination between the plasmid pAdCMV-HASS-MSP-1 19 and pJM17: homology regions pAdCMV-HASS-MSP-1 i 9 (Ad Ad 0-1 and 9 -16) undergo pairing and recombination with pJM17 and the expression cassette with MSP-1 19 is transferred into the genome of the adenovirus 5 E1 eliminating pBRx with the insert.
- FIGURE 12 Schematic representation of the cloning site of pAdCMV-SP- 19 , SVV CMV promoter and poly A tail.
- the sequence corresponding to HASS-MSP-I 19 is located between the Not ⁇ and Hind ⁇ site.
- the location of the primers used is represented by arrows.
- FIGURE 13 Selection of positive clone by digestion with restriction enzymes EcoRV and Hind ⁇ , and digestions of the same clone with enzymes SamHI, EcoRV and Hind ⁇ .
- PM Promega 100bp molecular weight standard, 1: undigested clone, 2: SamHI-digested (387 bp), 3: Hind-digested (454bp), 4: EcoRV-digested (412bp), 5: digested with EcoRV and Hind (388bp).
- FIGURE 14 Selection of positive clones by digestion with restriction enzymes EcoRV and Hind. Positive clones pAdCMV-MSP-1 19 show a fragment of 388pb. PM: 1kb Invitrogen. Channels 1 through 4: positive clones.
- FIGURE 15 HASS cloning process in pAdCMV-MSP-1 19: 1: Positive Clone Digestion pAdCMV-HASS-MSP-1 19 Partial with Not ⁇ , yielding a fragment of 1200pb 2: Digestion of the same clone with EcoRV, yielding a 625bp fragment that has been deleted from the vector. 3: New clone pAdCMV-HASS-MSP- 19 , which, when digested with Not ⁇ , yields a 560 bp fragment corresponding to the sequence of HASS-MSP- 19 .
- FIGURE 16 PCR and RT-PCR from DNA and viral RNA extracted from AdMSP-1 infected HEK293A 19 .
- 400bp amplicons were obtained with MSP-1 19 specific primers (channels 1 to 4 - viral DNA and channels 9 to 12 - viral RNA) and 500bp amplicons were obtained with adenovirus E4 gene specific primers (channels 5 to 8 - viral DNA and channels 14 to 16-viral RNA).
- rMSP-1 ig expressed in E. coli, CN: negative control
- AdMSP-1 expressed by recombinant adenovirus.
- Figure 18 MSP i 9 1 recombinant expressed in E. coli and the adenovirus detected by specific antibodies by western blot assay using sera from endemic area for malaria patients.
- rMSP- 19 expressed in E. coli, CN: negative control
- AdMSP-1 expressed by recombinant adenovirus.
- FIGURE 19 A: Transfer vector pAdCMV-Link-1: Cytomegalovirus (CMV) promoter, Cloning Site, polyadenylation site (poly A), HAdV5 homology regions. m.u: map unit.
- B HASS-AMA-1 cloned into pAdCMV-Link-1. The signal peptide was cloned at the BglW site, which after cloning this site was lost and AMA-1 was cloned at the EcoRV and Kpn ⁇ sites. * Enzyme sites used for HASS-AMA-1 cloning: BglW, EcoRV and Kpn.
- FIGURE 20 Schematic representation of homologous recombination between plasmids pAdCMV-HASS-AMA-1 and pJM17: Homology regions in pAdCMV-HASS-AMA-1 (Ad 0-1 and Ad 9 -16) undergo pairing and recombination with pJM17 and the AMA-1 expression cassette is transferred to the adenovirus 5 genome, eliminating E1 with the pBR insert.
- FIGURE 21 Selection of positive clones by digestion with restriction enzymes EcoRV and Kpn ⁇ . Positive clones have a 1431 bp fragment. PM: 1 kb promega, 1 to 4: pAdCMV-AMA-1 positive clones.
- FIGURE 22 Schematic representation of the 717bp fragment from pAd32.1, which was inserted into pAdCMV-AMA-1, with the initial 92 bases corresponding to the HASS sequence.
- FIGURE 23 BamH ⁇ and BglW restriction sites with compatible ends.
- FIGURE 24 Selection of positive clones by Not ⁇ digestion. Positive clones have a 2200bp fragment. PM: 1kb promega, 2, 4: positive clones, 6: negative clone, 1, 3 and 5: undigested plasmid DNA of respective clones in channels 2, 4 and 6.
- FIGURE 25 pAdCMV-AMA-1: 1 HASS cloning process: Digestion of partial pAdCMV-HASS-AMA-1 positive clone with Not ⁇ , yielding a 2200bp 2 fragment: Digestion of the same clone with Eco RV, yielding a 625bp fragment that was deleted from the vector. 3: New clone pAdCMV-HASS-AMA-1, which when digested with Not ⁇ yields a 1600bp fragment corresponding to the sequence of HASS-AMA-1.
- FIGURE 26 PCR and RT-PCR from DNA and viral RNA extracted from AdAMA-1 infected HEK293A.
- 500bp amplicons were obtained with adenovirus E4 gene specific primers (channels 1 to 3 - viral DNA and channels 4 to 7 - viral RNA) and 1, 4Kb amplicons were obtained with AMA-1 specific primers (channels 8 to 11 - viral DNA and channels 12 to 16 - viral RNA).
- CP positive control
- pAdCMVAMA-1 viral DNA
- 3 negative control
- 4 DNAse-treated RNA RT-PCR
- 5 DNAse-treated RNA PCR
- 6 CP: pAdCMVAMA -1
- 7 CN
- 8 Molecular weight standard 1 Kb Promega
- 9 CP: pAdCMVAMA-1
- 10 viral DNA
- 11 CN
- 12 DNAse-treated RNA RT-PCR
- 13 RNA PCR DNAse-treated
- 14 CN, 15: CP.
- FIGURE 27 Recombinant AMA-1 expressed in E. coli and Adenovirus detected by specific antibodies using serum from animals immunized with AMA-1.
- rAMA- 1 Expressed in E. coli
- AdAMA-1 Expressed by adenovirus
- CN Negative Control.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009801603910A CN102575256A (zh) | 2009-05-05 | 2009-05-05 | 编码间日疟原虫抗原的经遗传修饰的序列 |
BRPI0924581A BRPI0924581A2 (pt) | 2009-05-05 | 2009-05-05 | seqüências geneticamente modificadas de antígenos de plasmodium vivax, composições vacinais contendo proteínas recombinantes e vírus recombinantes que expressam esses antígenos e método de vacinação dose-reforço contra malária |
PCT/BR2009/000130 WO2010127420A1 (pt) | 2009-05-05 | 2009-05-05 | Sequências geneticamente modificadas de antígenos de plasmodium vivax |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/BR2009/000130 WO2010127420A1 (pt) | 2009-05-05 | 2009-05-05 | Sequências geneticamente modificadas de antígenos de plasmodium vivax |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010127420A1 true WO2010127420A1 (pt) | 2010-11-11 |
WO2010127420A9 WO2010127420A9 (pt) | 2010-12-29 |
Family
ID=43049863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2009/000130 WO2010127420A1 (pt) | 2009-05-05 | 2009-05-05 | Sequências geneticamente modificadas de antígenos de plasmodium vivax |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN102575256A (pt) |
BR (1) | BRPI0924581A2 (pt) |
WO (1) | WO2010127420A1 (pt) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001055181A2 (en) * | 2000-01-31 | 2001-08-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, Centers For Disease Control And Prevention | Recombinant multivalent malarial vaccines against plasmodium vivax |
WO2008122817A2 (en) * | 2007-04-10 | 2008-10-16 | Isis Innovation | Immunogenic compositions |
-
2009
- 2009-05-05 CN CN2009801603910A patent/CN102575256A/zh active Pending
- 2009-05-05 WO PCT/BR2009/000130 patent/WO2010127420A1/pt active Application Filing
- 2009-05-05 BR BRPI0924581A patent/BRPI0924581A2/pt not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001055181A2 (en) * | 2000-01-31 | 2001-08-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, Centers For Disease Control And Prevention | Recombinant multivalent malarial vaccines against plasmodium vivax |
WO2008122817A2 (en) * | 2007-04-10 | 2008-10-16 | Isis Innovation | Immunogenic compositions |
Also Published As
Publication number | Publication date |
---|---|
WO2010127420A9 (pt) | 2010-12-29 |
BRPI0924581A2 (pt) | 2016-07-19 |
CN102575256A (zh) | 2012-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11857640B2 (en) | Simian adenovirus and hybrid adenoviral vectors | |
JP7113924B2 (ja) | 組み換え改変ワクシニアウイルスアンカラ(mva)フィロウイルスワクチン | |
US9951352B2 (en) | Poxvirus expression system | |
ES2871907T3 (es) | Portadores de vacuna de adenovirus de chimpancé | |
US10124048B2 (en) | Adenovirus vectors | |
JP4282095B2 (ja) | Cd8 t細胞免疫応答を発生するワクチン接種のための方法および試薬 | |
JP2019519252A (ja) | アデノウイルスベクター | |
US20100255075A1 (en) | CR-2 Binding Peptide P28 as Molecular Adjuvant for DNA Vaccines | |
WO2012023995A1 (en) | Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes | |
US20130045234A1 (en) | Neutralizing factors as vaccine adjuvants | |
WO2012042279A2 (en) | Viral vector immunogenic compositions | |
US20110064768A1 (en) | Immunogenic Compositions | |
Bruder et al. | Molecular vaccines for malaria | |
WO2010127420A1 (pt) | Sequências geneticamente modificadas de antígenos de plasmodium vivax | |
BRPI0706003B1 (pt) | Seqüência geneticamente modificada do antígeno ama-1 de plasmodium vivax, proteína recombinante ama-1 e adenovírus geneticamente modificado que expressa o antígeno ama-1 recombinante | |
BRPI0706004B1 (pt) | Seqüência geneticamente modificada do antígeno dbp (mt) de plasmodium vivax, proteína recombinante dbp e adenovírus geneticamente modificado que expressa o antígeno dbp recombinante | |
BRPI0704730B1 (pt) | Seqüencia geneticamente modificada do antígeno dbp (am) de plasmodium vivax, proteína recombinante dbp e adenovírus geneticamente modificado que expressa o antígeno dbp recombinante | |
BRPI0705880B1 (pt) | Seqüência geneticamente modificada do antígeno dbp (pa) de plasmodium vivax, proteína recombinante dbp e adenovírus geneticamente modificado que expressa o antígeno dbp recombinante |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980160391.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09844215 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 9087/DELNP/2011 Country of ref document: IN |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09844215 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI0924581 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI0924581 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111107 |